- βPeople who kept off most weight (under 25% regain) maintained nearly all their improved waist size, cholesterol, and insulin levels
- βThe study clearly maps how much heart and metabolic health worsens based on how much weight is regained β giving patients a useful benchmark
- βFindings reinforce that continued obesity treatment preserves real, measurable health benefits beyond just the number on the scale
| Journal | JAMA internal medicine |
| Year | 2026 |
| PMID | 41284285 |
What This Study Found
This research looked at what happens to people's health when they stop taking tirzepatide (Zepbound/Mounjaro), a medication used for obesity and diabetes. The study followed 308 adults who had already lost significant weight on tirzepatide for 36 weeks, then stopped the medication.
The Key Problem: Weight Comes Back
After stopping tirzepatide, most people regained weight within one year. Researchers divided participants into four groups based on how much of their lost weight they regained:
- Less than 25% regained β kept most of their weight loss (best outcome)
- 25% to 50% regained β moderate weight regain
- 50% to 75% regained β significant weight regain
- 75% or more regained β regained nearly all lost weight (worst outcome)
What Happened to Heart and Metabolic Health
The more weight people regained, the more their cardiometabolic health worsened. Here is what changed after stopping tirzepatide:
Waist Circumference
- Less than 25% regain: increased by only 0.8 cm (barely any change)
- 75%+ regain: increased by 14.7 cm β a significant rise
Blood Pressure (Systolic)
- Even those who kept most weight off saw blood pressure rise by about 7 points
- Those who regained the most saw a 10-point rise
Blood Sugar (HbA1c)
- People who kept weight off: small rise of 0.14%
- People who regained most weight: larger rise of 0.35%
Cholesterol and Insulin
- Those who regained 75%+ of weight saw cholesterol worsen by nearly 11% and fasting insulin rise by 26%
- Those who kept weight off showed little to no meaningful change in these measures
The Silver Lining
People who managed to keep their weight loss (less than 25% regain) largely maintained their improved waist size, cholesterol, and insulin levels. This shows that the health benefits of tirzepatide can be preserved β but only if weight loss is maintained.
What This Means for You
This study sends a clear message: obesity is a long-term condition that often requires ongoing treatment. Stopping medication without a plan to maintain weight loss can undo hard-won health improvements relatively quickly. Talk to your doctor before making any changes to your medication.
